Pricing & Access· August 18, 2026 · 16 min read
DTX401's August 23 PDUFA: Payers Face a Cornstarch-Replacement Gene Therapy
By Ran Chen#Gene Therapy#Rare Disease#Medicaid
Archive
Every article
460 articles across the biopharma commercial, regulatory, and access stack.
Generics· August 18, 2026 · 14 min read
Generic Wakix Approved but Cannot Launch Until 2030: The Orange Book Fence
By Ran Chen#Orange Book#Generics#Generic Entry
Pricing & Access· August 18, 2026 · 18 min read
Ziihera's August 25 Gastric Decision: Bispecific vs Trastuzumab Biosimilars
By Ran Chen#Oncology#HER2#Biosimilars
Biosimilars· August 17, 2026 · 18 min read
FDA Biosimilar Device Guidance: Presentations That Are Not Interchangeable
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Pricing & Access· August 17, 2026 · 25 min read
Medicaid's September 10 Deadline: The Coverage Trade for GENEROUS Pricing
By Ran Chen#Medicaid#Drug Pricing#Payer Policy
Pricing & Access· August 17, 2026 · 25 min read
Tavneos on Formularies as FDA Moves to Withdraw: The Coverage Dilemma
Pricing & Access· August 16, 2026 · 18 min read
Hepatitis C Treatment Access in 2026: Generic Economics, PA, and Sobriety
Specialty· August 16, 2026 · 17 min read
Leqembi IQLIK Launches: Subcutaneous Lecanemab Moves to Specialty Pharmacy
Policy· August 16, 2026 · 15 min read
Ten PBMs Commit to TrumpRx Cash Prices in Real-Time Tools: The Policy Ledger
By Ran Chen#PBM#Payer Policy#Formulary Strategy
Specialty· August 15, 2026 · 26 min read
Hidradenitis Suppurativa Access: Adalimumab Spread, Biologics, & Oral JAKs
By Ran Chen#Dermatology#Biosimilars#Interchangeability